ストックスクリーナーアプリを入手
11.04
1.34%
-0.15
プレマーケット:
11.10
0.06
+0.54%
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 04 - marketscreener.com
BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth - Investing.com
BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth By Investing.com - Investing.com UK
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Best Momentum Stock to Buy for June 4th - Nasdaq
biocryst pharmaceuticals extends cfo consulting agreement - Investing.com
BioCryst Extends Consulting Agreement with Former CFO - TipRanks
New Strong Buy Stocks for June 4th - Yahoo
Best Momentum Stock To Buy For June 4th - Barchart.com
BioCryst Pharmaceuticals Inc (BCRX) Shares Up 3.59% on Jun 3 - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 7 Strategic Hires, Grants 47,250 Restricted Stock Units - Stock Titan
BioCryst stock soars to 52-week high, hits $11.14 By Investing.com - Investing.com Canada
BioCryst stock soars to 52-week high, hits $11.14 - Investing.com India
BioCryst to Present New Data at 2025 Meeting of the European Aca - GuruFocus
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology | BCRX Stock News - GuruFocus
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire Inc.
BioCryst (BCRX) Highlights Positive Data on Berotralstat for HAE Treatment | BCRX Stock News - GuruFocus
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotrals - GuruFocus
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages | BCRX Stock News - GuruFocus
BioCryst reports efficacy of HAE drug across age groups - Investing.com
BioCryst Highlights Real-world Data Showing ORLADEYO® - GlobeNewswire
BCRXBiocryst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Drugmaker targets younger patients as revenue balloons - The Business Journals
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
BioCryst to Present at Upcoming Investor Conferences | BCRX Stock News - GuruFocus
BioCryst to Present at Upcoming Investor Conferences - The Manila Times
How To Trade (BCRX) - news.stocktradersdaily.com
Bank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Trading 3.62% Higher on May 22 - GuruFocus
Orladeyo reduces swelling rates in severe HAE: Real-world data - Angioedema News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy Rating - Defense World
Transcript : BioCryst Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
D. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst's Orladeyo up for FDA review in pediatric HAE patients - MSN
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo success, pipeline progress - Investing.com Nigeria
BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Best Momentum Stocks to Buy for May 9th - The Globe and Mail
BioCryst reports ORLADEYO reduces severe HAE attack rates By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (NASDAQ:BCRX) Cut to Buy at StockNews.com - Defense World
(BCRX) Long Term Investment Analysis - news.stocktradersdaily.com
BioCryst reports ORLADEYO reduces severe HAE attack rates - Investing.com Australia
BioCryst Presents New Real-world Evidence Showing Significant an - GuruFocus
BioCryst (BCRX) Highlights Significant HAE Attack Reductions with ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewswire
New Clinical Evidence: ORLADEYO Dramatically Reduces HAE Attacks in Both Teens and Severe Patients - Stock Titan
FDA to review Orladeyo application for young children with HAE - Angioedema News
FDA awards BioCryst’s Orladeyo NDA for paediatric HAE - Yahoo
The Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst (BCRX) Gains FDA Priority Review for Pediatric ORLADEYO - GuruFocus
Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan
FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years - Contemporary Pediatrics
INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients - Contemporary Pediatrics
1.38%
0.61%
大文字化:
|
ボリューム (24 時間):